Oral Laquinimod Unfortunately on hold
November 3, 2011 Laquinimod filing would be ‘premature’ Teva chief executive Shlomo Yanai also caused a bit of a stir…
Ocrelizumab Targets B Cells And Reduces MS-Related Brain Lesions
02 Nov 2011 Multiple sclerosis (MS) is a chronic and disabling disease, in which a person’s central nervous system (brain, spinal…
Stuart Schlossman
ORAL Laquinimod Halted MS Disability But Not Relapses
AMSTERDAM – The multiple sclerosis drug laquinimod did not reduce the risk of relapse in the BRAVO phase III trial,…
Stuart Schlossman
The Potential for another FDA approval for a New Oral MS Medication
AMSTERDAM — The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of…
Stuart Schlossman
MS drug has big promise, study suggests
Biogen Idec Inc., the world’s largest maker of multiple sclerosis medicines, gained the most in six months after the experimental…
Stuart Schlossman
The U.S. Food & Drug Administration (FDA) has accepted Sanofi’s new drug application (NDA) for oral teriflunomide as a potential therapy for people with relapsing forms of multiple sclerosis
Sanofi and its subsidiary, Genzyme, announced Thursday, October 20, that the U.S. Food & Drug Administration (FDA) has accepted Sanofi’s…
Stuart Schlossman
About BG-12 – Possibly the Next Oral MS medication
About BG-12 BG-12 (dimethyl fumarate) is an investigational oral therapy in late-stage clinical development for the treatment of RRMS, the…
Stuart Schlossman
Biogen’s Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
-240 mg of BG-12 Administered Either Twice or Three Times Daily Demonstrated Significant Clinical Effects- WESTON, Mass., Oct 21, 2011…
Stuart Schlossman
FDA Okays New Label Claim for Fingolimod (Gilenya)
By John Gever, Senior Editor, MedPage Today Published: August 02, 2011 The oral multiple sclerosis drug fingolimod (Gilenya) reduces T1 gadolinium-enhancing…
Stuart Schlossman
Teva’s Laquinimod fails to reduce MS relapse
Teva’s Copaxone Successor Fails in Latest Clinical Trial By Naomi Kresge Aug. 1 (Bloomberg) — Teva Pharmaceutical Industries Ltd.’s experimental…
Stuart Schlossman
